Lenvatinib Mesylate | Market Exclusivity | US | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Lenvatinib Mesylate
US Exclusivities

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

Contact Supplier

Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

Contact Supplier

xyz-pharma-m-2025-03-24

Contact Supplier

LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Contact Supplier

Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.

Contact Supplier

xyz-pharma-m-2025-03-17

Contact Supplier

Lenvatinib Mesylate

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

21 API Suppliers, 10 USDMF, 5 EU WC, 3 KDMF, 6 NDC API, 13 Listed Suppliers

21 API Suppliers
10 USDMF
5 EU WC
3 KDMF
6 NDC API
13 Listed Suppliers

DEVELOPMENTS

7 Drugs in Development

7 Drugs in Development

INTERMEDIATES

1 Intermediate Suppliers

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

16 FDF Dossiers, 4 FDA Orange Book, 4 Europe, 8 Canada

16 FDF Dossiers
4 FDA Orange Book
4 Europe
8 Canada

DIGITAL CONTENT

9 News #PharmaBuzz

9 News #PharmaBuzz

MARKET PLACE

1 APIs

1 APIs

PATENTS & EXCLUSIVITIES

32 US Patents, 8 US Exclusivities, 16 Health Canada Patents

32 US Patents
8 US Exclusivities
16 Health Canada Patents

Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Name Reset all filters

8 All

01 8EISAI INC

filter Product Reset all filters

8 All

01 8LENVATINIB MESYLATE

filter Exclusivity Expiration Date Reset all filters

8 All

01 22025-08-15

02 22026-02-15

03 22027-04-03

04 22027-10-03

filter Exclusivity Code Reset all filters

8 All

01 2M-14

02 2ODE-196

03 4PED

Product Main Page

EISAI INC

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

LENVATINIB MESYLATE

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Exclusivity Code

ODE-196

Exclusivity Expiration Date

2025-08-15

Application Number

206947

Product Number

2

Exclusivity Details

01

EISAI INC

LENVATINIB MESYLATE

Immuno-Oncology 360

Not Confirmed

EISAI INC

U.S.A

Immuno-Oncology 360

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

LENVATINIB MESYLATE

Exclusivity Code : ODE-196

Exclusivity Expiration Date : 2025-08-15

Application Number : 206947

Product Number : 2

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

EISAI INC

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

LENVATINIB MESYLATE

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Exclusivity Code

M-14

Exclusivity Expiration Date

2027-04-03

Application Number

206947

Product Number

1

Exclusivity Details

02

EISAI INC

LENVATINIB MESYLATE

Immuno-Oncology 360

Not Confirmed

EISAI INC

U.S.A

Immuno-Oncology 360

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

LENVATINIB MESYLATE

Exclusivity Code : M-14

Exclusivity Expiration Date : 2027-04-03

Application Number : 206947

Product Number : 1

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

EISAI INC

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

LENVATINIB MESYLATE

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Exclusivity Code

ODE-196

Exclusivity Expiration Date

2025-08-15

Application Number

206947

Product Number

1

Exclusivity Details

03

EISAI INC

LENVATINIB MESYLATE

Immuno-Oncology 360

Not Confirmed

EISAI INC

U.S.A

Immuno-Oncology 360

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

LENVATINIB MESYLATE

Exclusivity Code : ODE-196

Exclusivity Expiration Date : 2025-08-15

Application Number : 206947

Product Number : 1

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

EISAI INC

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

LENVATINIB MESYLATE

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Exclusivity Code

PED

Exclusivity Expiration Date

2027-10-03

Application Number

206947

Product Number

2

Exclusivity Details

04

EISAI INC

LENVATINIB MESYLATE

Immuno-Oncology 360

Not Confirmed

EISAI INC

U.S.A

Immuno-Oncology 360

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

LENVATINIB MESYLATE

Exclusivity Code : PED

Exclusivity Expiration Date : 2027-10-03

Application Number : 206947

Product Number : 2

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

EISAI INC

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

LENVATINIB MESYLATE

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Exclusivity Code

PED

Exclusivity Expiration Date

2027-10-03

Application Number

206947

Product Number

1

Exclusivity Details

05

EISAI INC

LENVATINIB MESYLATE

Immuno-Oncology 360

Not Confirmed

EISAI INC

U.S.A

Immuno-Oncology 360

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

LENVATINIB MESYLATE

Exclusivity Code : PED

Exclusivity Expiration Date : 2027-10-03

Application Number : 206947

Product Number : 1

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

EISAI INC

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

LENVATINIB MESYLATE

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Exclusivity Code

PED

Exclusivity Expiration Date

2026-02-15

Application Number

206947

Product Number

2

Exclusivity Details

06

EISAI INC

LENVATINIB MESYLATE

Immuno-Oncology 360

Not Confirmed

EISAI INC

U.S.A

Immuno-Oncology 360

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

LENVATINIB MESYLATE

Exclusivity Code : PED

Exclusivity Expiration Date : 2026-02-15

Application Number : 206947

Product Number : 2

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

EISAI INC

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

LENVATINIB MESYLATE

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Exclusivity Code

PED

Exclusivity Expiration Date

2026-02-15

Application Number

206947

Product Number

1

Exclusivity Details

07

EISAI INC

LENVATINIB MESYLATE

Immuno-Oncology 360

Not Confirmed

EISAI INC

U.S.A

Immuno-Oncology 360

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

LENVATINIB MESYLATE

Exclusivity Code : PED

Exclusivity Expiration Date : 2026-02-15

Application Number : 206947

Product Number : 1

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

EISAI INC

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

LENVATINIB MESYLATE

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Exclusivity Code

M-14

Exclusivity Expiration Date

2027-04-03

Application Number

206947

Product Number

2

Exclusivity Details

08

EISAI INC

LENVATINIB MESYLATE

Immuno-Oncology 360

Not Confirmed

EISAI INC

U.S.A

Immuno-Oncology 360

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

LENVATINIB MESYLATE

Exclusivity Code : M-14

Exclusivity Expiration Date : 2027-04-03

Application Number : 206947

Product Number : 2

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!